The key details to know:
1. For the three month period that ended in December 2018, revenue totaled $2.4 million, compared to $933,000 for the same period year-over-year.
2. For the six month transition period that ended in December 2018, revenues totaled $2.9 million, compared to the same period year-over-year.
3. Cash and equivalents in December 2018 totaled $45.3 million compared to $38.8 million in June 2018.
4. In February, the company secured $60 million in debt facility with CR Group L.P., and plan to use the funding to retire a previous secured term loan provide working capital to support commercial launches of two products.
More articles on supply chain:
ASC supply chain tip of the day: Evaluate Amazon
EyePoint Pharmaceuticals launches Dexycu commercially in the US: 3 key details
ASC supply chain tip of the day: Leverage market share & volume
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
